Abstract
A 76-year-old man with newly diagnosed high-risk prostate cancer was referred for primary staging with F-18-PSMA-1007 PET/CT. The PET/CT scan showed no lymph node or bone metastases, only localized disease within the prostate gland. Additionally, the F-18-PSMA PET/CT scan showed a PSMA-positive lesion correlating to a polyp located in the body of the stomach on the greater curvature. A prior F-18-FDG PET/CT showed low FDG uptake in the polyp, but this was not reported initially in the written report. The patient had no upper gastrointestinal symptoms. A gastroscopy with biopsies was performed, and the histopathology results showed chronic unspecific inflammation with no granulomas, dysplastic or malignant changes in three out of three biopsies. A repeated gastroscopy with biopsy showed an epithelioid variant of a gastrointestinal stromal tumor (Ki-67 index 2%). A laparoscopic tumor extirpation was planned after radiation treatment in combination with endocrine therapy of the localized prostate cancer. To our knowledge, this is one of very few reported cases of a PSMA-positive gastrointestinal stromal tumor (GIST), and can be added to the list of malignant pitfalls of PSMA PET/CT in prostate cancer patients.
A 76-year-old man with newly diagnosed prostate cancer. The PSA level was 13 μg/L. Gleason 4 + 4 = 8 was found in 11 of 12 biopsies, alongside a cT2c tumor and a prostate volume of 20 ccm. About one month prior to the diagnosis, the patient was referred for an 18-F-FDG-PET/CT for unspecific symptoms, moderate elevation of C-reactive protein level and fever in order to locate infection sites or active inflammation, with the secondary aim of ruling out an underlying cancer. The patient had a medical history of methotrexate-treated seropositive rheumatoid arthritis. The F-18-FDG PET/CT showed localized uptake in the prostate and reactive mediastinal lymph nodes, and low FDG uptake (SUVmax 2.8) in a 35 mm polyp in the body of the stomach (Figure 1, Panel C and D). The latter was not mentioned in either the CT or PET report.
Figure 1.
The maximum intensity projection (MIP) of the F-18-PSMA-1007 PET/CT (A) show a PSMA-positive lesion located in the upper abdomen (arrow) (R, right side; L, left side). Transaxial images of the of the F-18-PSMA-1007 PET/CT (B) show the PSMA-positive polyp in the body of the stomach, as indicated by the arrows. The maximum intensity projection (MIP) (C) and transaxial images (D) of the prior F-18-FDG PET/CT showed low FDG uptake in the polyp (arrows).
One month later, the patient was referred for primary staging with F-18-PSMA-1007 PET/CT. The scan showed localized disease within the prostate with no sign of involvement of the seminal vesicles, lymph nodes or bones. Additionally, the scan showed a PSMA-positive lesion (SUVmax = 21) in the body of the stomach on the greater curvature, correlating to a 35 mm polyp located close to the pylorus (Figure 1, Panel A and B).
A gastroscopy with biopsies initially showed chronic unspecific inflammation with no granulomas, dysplastic or malignant changes in three out of three biopsies. A repeat biopsy showed an epithelioid variant of a low malignant gastrointestinal stromal tumor (Ki-67 index 2%). A laparoscopic tumor extirpation was planned after radiation treatment in combination with endocrine therapy of the localized prostate cancer.
Increased PSMA expression is seen in most prostate cancers but has also been reported in other malignant and benign conditions [1,2,3]. PSMA PET is now widely used for detecting biochemical recurrence of prostate cancer [4] but is also increasingly used for primary staging of high-risk prostate cancer [5]. To our knowledge, this is one of very few reports [6,7] demonstrating PSMA-positive GIST. The other reported GIST cases were localized in the small bowel and in the gastric fundus. PSMA-PET could potentially be a competitive tracer of F-18-FDG-PET for the staging of GIST. However, a systematic review and meta-analysis by Kim and Lee [8] showed a high pooled FDG sensitivity of 88% in 177 patients across seven studies. In our case, the GIST tumor was not detected in the initial F-18-FDG PET/CT, but only in the following F-18-PSMA PET/CT. GIST tumors can be added to the list of PSMA-positive malignant pitfalls when reporting PSMA PET/CT scans in prostate cancer patients. This is likely due to PSMA binding to endothelial cells of the neovasculature, as seen in other PSMA-positive non-prostate cancers.
Author Contributions
All authors have contributed equally to the evaluation of the clinical PET scans and to the drafting and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Written informed consent has been obtained from the patient to publish this article.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Rauscher, I.; Kronke, M.; Konig, M.; Gafita, A.; Maurer, T.; Horn, T.; Schiller, K.; Weber, W.; Eiber, M. Matched-Pair Comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. J. Nucl. Med. 2020, 61, 51–57. [Google Scholar] [CrossRef] [PubMed]
- Shetty, D.; Patel, D.; Le, K.; Bui, C.; Mansberg, R. Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review. Tomography 2018, 4, 182–193. [Google Scholar] [CrossRef] [PubMed]
- Sheikhbahaei, S.; Werner, R.A.; Solnes, L.B.; Pienta, K.J.; Pomper, M.G.; Gorin, M.A.; Rowe, S.P. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Semin. Nucl. Med. 2019, 49, 255–270. [Google Scholar] [CrossRef] [PubMed]
- Ware, R.E.; Williams, S.; Hicks, R.J. Molecular Imaging of Recurrent and Metastatic Prostate Cancer. Semin. Nucl. Med. 2019, 49, 280–293. [Google Scholar] [CrossRef]
- Klingenberg, S.; Jochumsen, M.R.; Ulhoi, B.P.; Fredsoe, J.; Sorensen, K.D.; Borre, M.; Bouchelouche, K. (68)Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. J. Nucl. Med. 2021, 62, 214–220. [Google Scholar] [CrossRef]
- Vaz, S.; Oliveira, C.; Castanheira, J.C.; Silva, Â.F.; Costa, D.C. Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology. Clin. Nucl. Med. 2018, 43, e488–e491. [Google Scholar] [CrossRef]
- Lee, D.J.W.; Warner, M.; Shannon, T.; Moschilla, J. Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan. J. Med. Imaging Radiat. Oncol. 2021, 65, 89–91. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.J.; Lee, S.W. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2018, 33, 576–582. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).